Inovio Pharmaceuticals, Inc. (INO) EPS Estimated At $-0.27 as of May, 9

Marco Green
Апреля 23, 2018

Out of rating recommendations 2 have given the stock a Buy while 4 recommend the stock as Outperform. Inovio Pharma Cmn (NASDAQ:INO)'s price sits 1.79% above from its SMA 50 of $4.71 and -12.13% far from the SMA 200 which is at $4.84.

Inovio Pharmaceuticals (NASDAQ:INO) has been given a $13.00 target price by equities researchers at HC Wainwright in a report released on Thursday, April 12th. On Wednesday, January 3 the rating was maintained by H.C. Wainwright with "Buy".

Inovio Pharma Cmn (NASDAQ:INO)'s revenue estimates for the current quarter are $16.44 Million according to 4 number of analysts, for the current quarter the company has high revenue estimates of $25.7 Million in contradiction of low revenue estimates of $7 Million. ValuEngine lowered Inovio Pharmaceuticals from a sell rating to a strong sell rating in a research report on Thursday, March 1st. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the stock. "Buy" rating has 2, "Sell" are 0, while 0 are "Hold". 748,552 shares of the stock traded hands, compared to its average volume of 1,378,558.

Inovio Pharmaceuticals stock opened at $4.64 on Thursday. After $-0.24 EPS was revealed last quarter, analysts now see negative EPS growth of 12.50 % for Inovio Pharmaceuticals, Inc.

First-quarter earnings reports have grabbed shareholders' attention this week, with Netflix Inc., Goldman Sachs Group Inc. and UnitedHealth Group Inc. among the companies that have posted encouraging results. With 53,200 avg volume, 9 days are for Kingold Jewelry Inc (NASDAQ:KGJI)'s short sellers to cover KGJI's short positions. Total debt to equity ratio of Inovio Pharma Cmn (NASDAQ:INO) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. During the same period in the prior year, the business posted ($0.35) EPS. Analysts predict $-0.27 EPS, which is $0.04 up or 12.90 % from 2017's $-0.31 EPS.

In other news, Director David B. Weiner sold 9,000 shares of the company's stock in a transaction dated Monday, April 16th. The average target $13.50 is 190.95% above the last ($4.64) price. Following the completion of the sale, the director now owns 758,956 shares of the company's stock, valued at $3,726,473.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 116,500 shares of company stock valued at $597,078. A stock with a beta less than 1 is considered less volatile than the market; more than 1 means more volatile. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company's stock worth $1,856,000 after buying an additional 320,376 shares during the period. Oil futures pulled back from 3 1/2 year high to settle 0.3% lower at $68.29. Most company stocks have very little volatility.

Several hedge funds and other institutional investors have recently modified their holdings of INO. The company has a market capitalization of $427.61, a price-to-earnings ratio of -4.36 and a beta of 2.55. Vident Investment Advisory LLC now owns 291,713 shares of the biopharmaceutical company's stock valued at $1,205,000 after buying an additional 142,328 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Inovio Pharmaceuticals by 17.4% during the third quarter. "Buy" rating has 2, "Sell" are 0, while 0 are "Hold".

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by StockNewsTimes and is owned by of StockNewsTimes.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.The company has $420.85 million market cap. The mean target projections are based on 6 opinions.

Other reports by

Discuss This Article